{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:20:35Z","timestamp":1780460435670,"version":"3.54.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"DOI":"10.7759\/cureus.91432","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T20:15:27Z","timestamp":1756757727000},"source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Vildagliptin Versus Other Dipeptidyl Peptidase 4 (DPP-4) Inhibitors in the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials"],"prefix":"10.7759","author":[{"given":"Vinodhini","family":"Selvaraj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S002","article-title":"2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024","volume":"47","year":"2024","unstructured":"2. Diagnosis and Classification of Diabetes. Standards of Care in Diabetes-2024. Diabetes Care. 2024, 47:S20-42. 10.2337\/dc24-S002","journal-title":"Diabetes Care"},{"key":"ref2","unstructured":"International Diabetes Federation. IDF Diabetes Atlas. 11th ed. Brussels, Belgium. International Diabetes Federation. (2025). Accessed: August 26, 2025: https:\/\/idf.org\/about-diabetes\/diabetes-facts-figures\/."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1882","article-title":"The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients","volume":"92","author":"Balas B","year":"2007","unstructured":"Balas B, Baig MR, Watson C, et al.. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007, 92:1249-55. 10.1210\/jc.2006-1882","journal-title":"J Clin Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-015-0841-1","article-title":"Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes","volume":"52","author":"Bekiari E","year":"2016","unstructured":"Bekiari E, Rizava C, Athanasiadou E, et al.. Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. Endocrine. 2016, 52:458-80. 10.1007\/s12020-015-0841-1","journal-title":"Endocrine"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1135","article-title":"Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes","volume":"94","author":"D'Alessio DA","year":"2009","unstructured":"D'Alessio DA, Denney AM, Hermiller LM, et al.. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2009, 94:81-8. 10.1210\/jc.2008-1135","journal-title":"J Clin Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker DJ","year":"2006","unstructured":"Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006, 368:1696-705. 10.1016\/S0140-6736(06)69705-5","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.13561","article-title":"Efficacy and safety profile of sitagliptin, vildagliptin, and metformin in newly diagnosed type 2 diabetic subjects","volume":"48","author":"Elhini SH","year":"2021","unstructured":"Elhini SH, Hussien AK, Omran AA, Elsayed AA, Saeed H. Efficacy and safety profile of sitagliptin, vildagliptin, and metformin in newly diagnosed type 2 diabetic subjects. Clin Exp Pharmacol Physiol. 2021, 48:1589-602. 10.1111\/1440-1681.13561","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2012.06.001","article-title":"Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study","volume":"38","author":"Guerci B","year":"2012","unstructured":"Guerci B, Monnier L, Serusclat P, et al.. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study. Diabetes Metab. 2012, 38:359-66. 10.1016\/j.diabet.2012.06.001","journal-title":"Diabetes Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3460-0","article-title":"Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"58","author":"Inzucchi SE","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al.. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015, 58:429-42. 10.1007\/s00125-014-3460-0","journal-title":"Diabetologia"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi SE","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al.. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015, 38:140-9. 10.2337\/dc14-2441","journal-title":"Diabetes Care"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad AR","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, et al.. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996, 17:1-12. 10.1016\/0197-2456(95)00134-4","journal-title":"Control Clin Trials"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ16-0266","article-title":"Comparative effects of vildagliptin and sitagliptin determined by continuous glucose monitoring in patients with type 2 diabetes mellitus","volume":"63","author":"Koyanagawa N","year":"2016","unstructured":"Koyanagawa N, Miyoshi H, Ono K, et al.. Comparative effects of vildagliptin and sitagliptin determined by continuous glucose monitoring in patients with type 2 diabetes mellitus. Endocr J. 2016, 63:747-53. 10.1507\/endocrj.EJ16-0266","journal-title":"Endocr J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10010081","article-title":"Plant extracts for type 2 diabetes: from traditional medicine to modern drug discovery","volume":"10","author":"Lee J","year":"2021","unstructured":"Lee J, Noh S, Lim S, Kim B. Plant extracts for type 2 diabetes: from traditional medicine to modern drug discovery\r\n. Antioxidants (Basel). 2021, 10:81. 10.3390\/antiox10010081","journal-title":"Antioxidants (Basel)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/1758-5996-6-69","article-title":"Efficacy and safety of vildagliptin, saxagliptin or sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents","volume":"6","author":"Li CJ","year":"2014","unstructured":"Li CJ, Liu XJ, Bai L, Yu Q, Zhang QM, Yu P, Yu DM. Efficacy and safety of vildagliptin, saxagliptin or sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents. Diabetol Metab Syndr. 2014, 6:69. 10.1186\/1758-5996-6-69","journal-title":"Diabetol Metab Syndr"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-0334-z","article-title":"Young-onset type 2 diabetes mellitus - implications for morbidity and mortality","volume":"16","author":"Magliano DJ","year":"2020","unstructured":"Magliano DJ, Sacre JW, Harding JL, Gregg EW, Zimmet PZ, Shaw JE. Young-onset type 2 diabetes mellitus - implications for morbidity and mortality. Nat Rev Endocrinol. 2020, 16:321-31. 10.1038\/s41574-020-0334-z","journal-title":"Nat Rev Endocrinol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-0612-8","article-title":"Cardiovascular risk in type 1 diabetes mellitus","volume":"10","author":"Schofield J","year":"2019","unstructured":"Schofield J, Ho J, Soran H. Cardiovascular risk in type 1 diabetes mellitus\r\n. Diabetes Ther. 2019, 10:773-89. 10.1007\/s13300-019-0612-8","journal-title":"Diabetes Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2007.02191.x","article-title":"Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-na\u00efve patients with type 2 diabetes","volume":"24","author":"Schweizer A","year":"2007","unstructured":"Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-na\u00efve patients with type 2 diabetes. Diabet Med. 2007, 24:955-61. 10.1111\/j.1464-5491.2007.02191.x","journal-title":"Diabet Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ16-0341","article-title":"Comparative analysis of the effects of alogliptin and vildagliptin on glucose metabolism in type 2 diabetes mellitus","volume":"64","author":"Tanaka K","year":"2017","unstructured":"Tanaka K, Okada Y, Mori H, et al.. Comparative analysis of the effects of alogliptin and vildagliptin on glucose metabolism in type 2 diabetes mellitus. Endocr J. 2017, 64:179-89. 10.1507\/endocrj.EJ16-0341","journal-title":"Endocr J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1530\/EC-18-0523","article-title":"Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in Chinese diabetes: a randomized clinical trial","volume":"8","author":"Zhou XJ","year":"2019","unstructured":"Zhou XJ, Ding L, Liu JX, Su LQ, Dong JJ, Liao L. Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in Chinese diabetes: a randomized clinical trial. Endocr Connect. 2019, 8:318-25. 10.1530\/EC-18-0523","journal-title":"Endocr Connect"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-03669-y","article-title":"Undiagnosed diabetes mellitus and associated factors among adults in Ethiopia: a systematic review and meta-analysis","volume":"11","author":"Yitbarek GY","year":"2021","unstructured":"Yitbarek GY, Ayehu GW, Asnakew S, et al.. Undiagnosed diabetes mellitus and associated factors among adults in Ethiopia: a systematic review and meta-analysis. Sci Rep. 2021, 11:24231. 10.1038\/s41598-021-03669-y","journal-title":"Sci Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/386903-efficacy-and-safety-of-vildagliptin-versus-other-dipeptidyl-peptidase-4-dpp-4-inhibitors-in-the-management-of-type-2-diabetes-mellitus-a-systematic-review-of-randomized-controlled-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T20:15:28Z","timestamp":1756757728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/386903-efficacy-and-safety-of-vildagliptin-versus-other-dipeptidyl-peptidase-4-dpp-4-inhibitors-in-the-management-of-type-2-diabetes-mellitus-a-systematic-review-of-randomized-controlled-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.91432","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}